News & Blog

News & Blog

News | Oct 7 2026

Community Statement: Neurocrine Biosciences announces the first clinical study of NBIB-223 (the FACET™ study), An investigational gene therapy for FA

Industry News
News | Feb 26 2024

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that t...

Industry News
News | Jan 29 2019

Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for seve...

Industry News